Bharat Book Bureau

Rising neurodegenerative disease prevalence and expanding patent populations - where are the best opportunities and how can you unlock these? Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains.

The ageing of the baby-boom generation, combined with new and emerging treatments for neurodegenerative disorders - including multiple sclerosis, Alzheimer’s disease and Parkinson’s disease - will lead to further expansion of the neurodegenerative therapies market. Increasing disease prevalence and a robust pipeline make that sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains why, revealing where the most-exciting developments will lie from the present onwards.

This report examines markets for treating the following disorders in particular:
• Parkinson’s disease
• Alzheimer’s disease
• Multiple sclerosis
• Amyotrophic lateral sclerosis
• Neuropathies.

Also covered are the following neurodegenerative disorders:
• Huntington’s disease
• Prion diseases.

What types of therapeutic agent are likely to enter the market from 2009 onwards, and will they hold the potential to dominate this market area? Where will the best commercial opportunities lie from 2009 onwards? What are the most-crucial drivers and restraints in this market? This report will provide you with the information that you need to understand current trends and future directions in neurodegenerative disorder therapies. In particular, we discuss prospects for the following products in detail:

• Sifrol
• Stalevo
• Requip
• Aricept
• Namenda
• Exelon
• Reminyl
• Avonex
• Copaxone
• Rebif
• Betaferon
• Rilutek.

In our pipeline analyses we include emerging therapeutics such as stem cells, gene therapy and monoclonal antibodies, among other prominent developments.

Detailed analysis of the neurodegenerative disorders market sector

World Neurodegenerative Diseases Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 63 tables and figures included, as well as three full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Research interviews from our comprehensive survey

This report contains visiongain interviews with the following relevant experts:
1) Dr Johan Luthman, former Global Head of Exploratory Medicine (Neurology, Autoimmune & Inflammatory Diseases), Merck Serono
2) Dr Allan Tobin, Senior Scientific Advisor to the CHDI Foundation
3) Professor Peter Jenner, founder and Chief Science Officer, Proximagen Neurosciences, and Professor in Pharmacology, King’s College, University of London.

Why you should buy World Neurodegenerative Diseases Market 2009-2024

In this report you will receive the following benefits in particular:
• You will assess the current market for neurodegenerative disease therapeutics
• You will review the overall neurodegenerative disease therapeutics market, including a global sales forecast for 2009 to 2024
• You will receive sales forecasts for neurodegenerative disorder submarkets from 2009 to 2024, with detailed discussions
• You will receive sales forecasts for leading products from 2009 to 2024, with detailed discussions of market potential and competition
• You will receive sales forecasts for leading geographical markets from 2009 to 2024, with informed discussion
• You will examine commercial drivers and restraints in depth
• You will discover the most-exciting pipeline developments in the sector, with informed commentary
• You will discover expert opinions from our original survey of the sector, with prominent contributions from industry and academia.

You can obtain this report today

Nobody with an interest in the neurodegenerative diseases sector can afford to overlook this new market study. We predict that total revenues will increase throughout our forecast period, 2009 to 2024. With rising disease prevalence and expanding patient populations - coupled with high economic and social costs of those diseases - this therapeutic area holds significant potential for revenue growth. Do you want to harness those opportunities? You can stay ahead by ordering this report today.

Table of Contents:

1. Executive Summary
1.1 Aims of this Report
1.2 Chapter Breakdown

2. Neurodegenerative Diseases: An Introduction
2.1 What Are Neurodegenerative Diseases?
2.2 Prevalence and Economic Impact
2.3 Types of Neurodegenerative Diseases
2.3.1 Parkinson’s Disease
2.3.2 Alzheimer’s Disease
2.3.3 Multiple Sclerosis
2.3.4 Huntington’s Disease
2.3.5 Amyotrophic Lateral Sclerosis
2.3.6 Neuropathies
2.3.7 Prion Diseases

3. Neurodegenerative Diseases, Global Market 2009-2024
3.1 Analysis of the Current Market
3.2 Neurodegenerative Diseases, Forecast 2009-2024
3.3 Symptomatic Treatment
3.4 Multiple Sclerosis at the Forefront of the Market
3.5 Future Directions

4. Parkinson’s Disease
4.1 Prevalence and Economic Impact
4.2 Current Treatment Options
4.3 Parkinson’s Disease Market Forecast 2009-2024
4.4 Sifrol Forecast 2009-2024
4.4.1 Patent Expiries
4.5 Stalevo Forecast 2009-2024
4.5.1 Patent Expiries and Generic Challenges
4.5.2 The FIRST STEP trial
4.6 ReQuip Forecast 2009-2024
4.6.1 Patents and Lifecycle Management
4.7 Concluding Remarks

5. Alzheimer’s Disease
5.1 Prevalence and Economic Impact
5.2 Treatment Options
5.3 Analysis of the Current Market
5.4 Alzheimer’s Disease Market Forecast 2009-2024
5.5 Aricept Forecast 2009-2024
5.5.1 Patents
5.6 Namenda Forecast 2009-2024
5.6.1 Patents and Generic Challenges
5.7 Exelon Forecast 2009-2024
5.7.1 Patent Expiries
5.8 Reminyl Forecast 2009-2024
5.8.1 Generic Challenges
5.9 Future Directions and Concluding Remarks

6. Multiple Sclerosis
6.1 Economic and Social Impact
6.1.1 Prevalence
6.2 Treatment Options
6.2.1 Treatment for Relapses
6.2.2 Treatment for Symptoms
6.2.3 Disease-Modifying Medicines
6.3 Analysis of the Current Market
6.4 Multiple Sclerosis Market Forecast 2009-2024
6.5 Avonex Forecast 2009-2024
6.5.1 Markets and Patent Expiries
6.5.2 Strong Competition Will Erode Market Share
6.6 Copaxone Forecast 2009-2024
6.6.1 A Unique Therapy - For Now
6.6.2 Forthcoming Patent Expiries
6.7 Rebif Forecast 2009-2024
6.7.1 New Delivery Mechanism to Improve Sales
6.7.2 Efficacy Studies
6.8 Betaferon Forecast 2009-2024
6.8.1 Patent Expiries
6.8.2 Strong Competition
6.9 Future Directions
6.9.1 The Re-Launch of Tysabri

7. Amyotrophic Lateral Sclerosis
7.1 Possible Causes of ALS
7.2 Prevalence
7.3 Treatment Options
7.4 Analysis of the Current Market
7.5 Amyotrophic Lateral Sclerosis Market Forecast 2009-2024
7.6 Rilutek Forecast 2009-2024
7.6.1 New Indications
7.6.2 Patents
7.7 Future Directions
7.7.1 Insmed’s Iplex

8. Neuropathies
8.1 Treating the Underlying Cause
8.2 Surgery and Physical Therapy
8.3 Pharmacological Treatments
8.3.1 Aldose Reductase Inhibitors
8.3.2 Antidepressants
8.3.3 Analgesics
8.3.4 Anticonvulsants
8.4 Analysis of the Current Market
8.4.1 Economic and Social Impact
8.4.2 Increasing Prevalence and Treatment Strategies
8.5 Neuropathies Market Forecast 2009-2024
8.6 Kinedak Forecast 2009-2024
8.6.1 Adverse Effects and Safety Warnings
8.6.2 Direct Competition in the Pipeline
8.7 Future Directions

9. Huntington’s Disease
9.1 Prevalence and Economic Impact
9.2 Treatment Options
9.2.1 Monoamine-Depleting Agents
9.2.2 Benzodiazepines
9.2.3 Dopamine Antagonists
9.3 Analysis of the Current Market and Future Directions

10. Prion Diseases
10.1 Creuztfeldt-Jacob Disease
10.2 Gerstmann-Straussler-Scheinker Disease
10.3 Kuru
10.4 Fatal Familial Insomnia
10.5 Prevalence
10.6 Analysis of the Current Market
10.6.1 Increasing Prevalence Could Alter the Market

11. Geographical Breakdown of the Market
11.1 USA
11.2 Europe
11.3 Emerging Markets
11.3.1 China versus India
11.3.2 Brazil
11.4 Concluding Remarks

12. Future Directions
12.1 Stem Cell Therapy for Neurodegenerative Diseases
12.2 Cybrids: “Disease in a Dish” Models
12.3 Gene Therapy: Promising Results
12.4 Hopes for Alzheimer’s Treatment
12.4.1 Monoclonal Antibody Bapineuzumab (AAB-001)
12.4.2 Monoclonal Antibody Solanezumab
12.5 The MS Pipeline
12.5.1 Monoclonal Antibodies for the Treatment of MS
12.5.2 Managing Immune Activity
12.5.3 Statins: A Further Role?
12.5.4 Concluding Remarks on the MS Pipeline
12.6 Huntington’s Disease: Future Developments
12.6.1 Dimebon
12.6.2 Cystamine
12.6.3 HDAC Inhibitors
12.6.4 RNAi as a Potential Treatment
12.6.5 The Case for Brain-Derived Neurotrophic Factor (BDNF)
12.6.6 What About Stem Cells and Gene Therapy?
12.7 ALS: The Pipeline
12.7.1 Knopp Neurosciences’ KNS-760704
12.7.2 CytRx Corporation’s Arimoclomol

13. Drivers and Restraints
13.1 Drivers in the Market
13.1.1 The Ageing Population and Increasing Prevalence
13.1.2 The MS Market: Oral Products May Expand Revenues
13.1.3 Advances in Research
13.1.4 Chronic Diseases: Long-Term Repeat Sales
13.1.5 Unmet Needs in the Patient Population
13.2 Restraints in the Market
13.2.1 High Product Competition
13.2.2 The High Cost of Treatment
13.2.3 The MS Market: Patient Compliance
13.2.4 Patent Expiries and Generic Competition
13.3 Concluding Remarks

14. Expert Opinions
14.1 Interview with Dr Johan Luthman
14.1.1 On Understanding the Disease and its Treatments
14.1.2 On Unmet Needs for Treatments
14.1.3 On Current Treatment Options
14.1.4 On Future Treatment Possibilities
14.1.5 On Stem Cell Media Coverage
14.1.6 On the Therapeutic and Curative Potential of Stem Cells for Neurological Diseases
14.1.7 On the Treatment of Neurological Diseases
14.1.8 On the Time Frame for Marketable Stem Cell Treatment Options
14.2 Interview with Dr Allan Tobin (CHDI Foundation)
14.2.1 On the Possibility of a Cure
14.2.2 On the Pipeline for Huntington’s Disease
14.2.3 On the Advantages and Disadvantages of Studying Huntington’s Disease
14.2.4 On the Market Value of a Treatment for Huntington’s Disease
14.3 Interview with Professor Peter Jenner (Proximagen Neurosciences and King’s College, University of London)
14.3.1 On the Challenges in the Treatment of Parkinson’s Disease
14.3.2 On Promising Therapeutics
14.3.3 On the Possibility of a Cure
14.3.4 On Stem Cells in the Treatment of Parkinson’s Disease
14.3.5 On Important Areas of Research

15. Conclusions
15.1 Multiple Sclerosis Treatments Lead the Market Area
15.2 Chronic Conditions and Treatment Options
15.3 Comments on the Global Market
15.4 Potential in the Pipeline
15.5 Geographical Opportunities

List of Tables
Table 2.1 Types of Neurodegenerative Diseases
Table 3.1 Neurodegenerative Diseases Market: World Sales ($m), 2008-2014, 2019 and 2024
Table 4.1 Parkinson’s Disease Symptoms
Table 4.2 Key Anti-Parkinson Drugs, World Sales ($m) and Market Share (%), 2008
Table 4.3 Anti-Parkinson’s Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
Table 5.1 FDA Approved Alzheimer’s Therapeutics, 2009
Table 5.2 Key Anti-Alzheimer’s Drugs, World Sales ($m) and Market Share (%), 2008
Table 5.3 Anti-Alzheimer’s Disease Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
Table 6.1 Multiple Sclerosis: Possible Risk Factors
Table 6.2 Multiple Sclerosis Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
Table 6.3 Leading MS Drugs, World Market Share (%), 2008, 2014, 2019 and 2024
Table 7.1 Factors Associated With the Onset of ALS
Table 7.2 Amyotrophic Lateral Sclerosis Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
Table 8.1 Apparent Causes for Neuropathy
Table 8.2 Top-Selling Local Anaesthetics ($m), 2008
Table 8.3 Key Therapeutics Indicated for Neuropathies, 2009
Table 8.4 Neuropathies Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
Table 9.1 Treatment Options for Huntington’s Disease, 2009
Table 10.1 Number of Suspected CJD and GSS Cases in the UK, 1998-2008
Table 11.1 The Neurodegenerative Market by Country, Sales ($m), CAGR (%) and Market Share (%), 2008-2014, 2019 and 2024
Table 12.1 Number of Pipeline Products by Phase and Disease, 2009
Table 12.2 Key Products in the MS Pipeline, 2009
Table 13.1 SWOT Analysis for Neurodegenerative Diseases, 2009

List of Figures
Figure 3.1 The Neurodegenerative Market World Sales ($m), 2008
Figure 3.2 Neurodegenerative Diseases Market World Sales ($m), 2008-2024
Figure 3.3 Neurodegenerative Market by Therapeutic Area, World Sales ($m), 2009, 2014 2019, 2024
Figure 4.1 Anti-Parkinson’s Therapeutics World Sales ($m), 2008-2024
Figure 4.2 Anti-Parkinson’s Drugs, World Market Share (%), 2008
Figure 4.3 Sifrol World Sales ($m), 2008-2024
Figure 4.4 Stalevo World Sales ($m), 2008-2024
Figure 4.5 ReQuip World Sales ($m), 2008-2024
Figure 5.1 Key Anti-Alzheimer’s Drugs, World Market Share (%), 2008
Figure 5.2 Anti-Alzheimer’s Disease Therapeutics World Sales ($m), 2008-2024
Figure 5.3 Anti-Alzheimer’s Disease Therapeutics World Sales ($m), 2009, 2014, 2019 and 2024
Figure 5.4 Aricept World Sales ($m), 2008-2024
Figure 5.5 Namenda World Sales ($m), 2008-2024
Figure 5.6 Exelon World Sales ($m), 2008-2024
Figure 5.7 Reminyl World Sales ($m), 2008-2024
Figure 6.1 Multiple Sclerosis Therapeutics World Sales ($m), 2008-2024
Figure 6.2 Key Multiple Sclerosis Therapeutic Products, World Sales ($m), 2008
Figure 6.3 Avonex World Sales ($m), 2008-2024
Figure 6.4 Copaxone World Sales ($m), 2008-2024
Figure 6.5 Rebif World Sales ($m), 2008-2024
Figure 6.6 Betaferon World Sales ($m), 2008-2024
Figure 6.7 Leading MS Drugs, World Market Share (%), 2008
Figure 6.8 Leading MS Drugs, World Market Share (%), 2024
Figure 6.9 Leading MS Drugs, World Sales ($m), 2008, 2014, 2019, 2024
Figure 7.1 Amyotrophic Lateral Sclerosis Therapeutics World Sales ($m), 2008-2024
Figure 7.2 Rilutek World Sales ($m), 2008-2024
Figure 7.3 Amyotrophic Lateral Sclerosis Therapeutics World Sales ($m), 2009, 2014, 2019 and 2024
Figure 8.1 Neuropathies Therapeutics World Sales ($m), 2008-2024
Figure 8.2 Neuropathic Pain and General Neuropathic Therapeutics, World Market Share (%), 2008
Figure 8.3 Neuropathic Pain and General Neuropathic Therapeutics, World Sales ($m), 2009, 2014, 2019 and 2024
Figure 8.4 Kinedak World Sales ($m), 2008-2024
Figure 8.5 Kinedak and Other General Neuropathic Products, World Sales ($m), 2008, 2014, 2019 and 2024
Figure 10.1 Number of Suspected CJD and GSS Cases in the UK, 1998-2008
Figure 11.1 The Neurodegenerative Market by Country, Sales ($m), 2009, 2014, 2019 and 2024
Figure 11.2 European Neurodegenerative Market, Sales ($m), 2009, 2014, 2019 and 2024
Figure 11.3 China, India and Brazil, Sales ($m), 2009, 2014, 2019 and 2024
Figure 11.4 Geographical Breakdown of the World Market, Sales ($m), 2008
Figure 11.5 Geographical Breakdown of the World Market, Sales ($m), 2024
Figure 12.1 Number of Pipeline Products by Phase and Disease, 2009
Figure 12.2 Number of Products in the Alzheimer’s Pipeline by Phase, 2009

Companies Listed
Acorda Therapeutics
Active Biotech
Aguettant
AstraZeneca
Bayer
Biogen Idec
BioMS Medical
Boehringer Ingelheim
Cobalt
CHDI Foundation
CytRx Corporation
Dainippon Sumitomo
Dr. Reddy’s Laboratories
Eisai
Elan
Eli Lilly
EMD Serono
EMEA
Endo
Forest
GlaxoSmithKline
Hermes
Insmed
InterMune
Johnson & Johnson
Knopp Neurosciences
Lundbeck
Lupin
Medivation
Merck & Co
Merck Serono
Merck KGaA
Momenta Pharmaceuticals
Mylan
Natco
Neuren
Novartis
Ono Pharmaceuticals
Orchid
Orion Corporation
Pfizer
Proximagen Neurosciences
ReceptoPharm
Roche
Roxane
Sanofi-Aventis
Sun Pharmaceuticals
Takeda
Teva
The Alzheimer’s Association
The European Medicines Agency
The Human Fertilisation and Embryology Authority
The National Academy of Sciences
The World Health Organisation (WHO)
Upsher-Smith
US Food and Drug Administration (FDA)
Watson Pharmaceuticals
Wockhardt
Wyeth

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/World-Neurodegenerative-Diseases-Market-2009-2024.html

OR Contact us at

Bharat Book Bureau
207, Hermes Atrium, Sector 11, PO Box.54, CBD Belapur, Navi Mumbai - 400 614, India.
Phone : +91 22 2757 8668 / 2757 9438
Fax : +91 22 2757 9131
E-mail : info@bharatbook.com
Website : www.bharatbook.com

Choices in Cord Blood Banking Factors Influencing Parental Decision Making

Cord blood banking is increasingly being used to improve and save lives. Stem cells derived from umbilical blood have been used in more than 14,000 transplants worldwide to treat a wide range of blood diseases, genetic and metabolic disorders, immunodeficiencies and various forms of cancer. However, many expectant parents still do not fully understand the significance of cord blood storage. A study published in the Journal of Reproductive Medicine shows that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as ¡§minimally informed.¨

Part 1 of this market report used proprietary data-derivation techniques to analyze conditions of the cord blood banking industry. Part 2 of this report used an end-user survey of expectant parents to identify and analyze the factors involved in the decision to privately store, publicly donate, or discard cord blood at birth. More than 1,200 expectation parents throughout the U.S., as well as Canada, Mexico, Europe, Asia, South/Central America, Australia and other regions answered the detailed survey between November 2008 and January 2009.
The report includes:

Sources through which expectant parents learn of cord blood banking
Rates of parental awareness of cord blood banking by gender, household income, geographic location, education, birth order, and other critical factors
Reasons parents cite as driving the decision to store cord blood
Factors influencing the decision for private vs. public storage of cord blood
Price sensitivity and quality expectations
Comparative analysis of quality variables among cord blood banks and parent perceptions of them
Parental responsiveness to health statistics
Differences in perspective based on global region, as well as differences due to location (city vs. suburban vs. rural)
Critical trends in cord blood banking and the factors influencing them
Competitive analysis of the Cord Blood Banking Industry, including:

U.S. Public Cord Blood Banks
U.S. Private Cord Blood Banks
International Public Cord Blood Banks
International Private Cord Blood Banks
Population Profiling: Characteristics of those highly/moderately/least likely to purchase cord blood banking services

Methods to effectively communicate with your target audience: Expectant Parents
And much more…

Table of Contents:

PART 1: CORD BLOOD BANKING, INDUSTRY OVERVIEW
I. Abstract
II. Cord Blood Stem Cells

A. Fetal Cord Blood Characteristics

B. Existing Treatments

C. Future Applications

III. Cord Blood Banking Industry

A. History

B. Private vs. Public Cord Blood Banks

1. U.S. Public Banks

a. Overview

b. Number of Public Banks

c. Geographic  Distribution

2. U.S. Private Banks

a. Overview

b. Number of U.S. Private Banks

c. Geographic  Distribution

3. Free Programs for U.S. Families with Medical Need

4. International Banks

a. Overview

b. Number Private Cord Blood Banks by International Region

IV. Market Characterization

A. List of U.S.  Private Cord Blood Banks

B. List of U.S. Public Cord Blood Banks

C. U.S. Mail-In Donation Cord Blood Banks

D. Breakdown of Canadian Cord Blood Banks – Public vs. Private / AABB Accredited vs. Non-Accredited

E. International Cord Blood Banks

1. Mexican Cord Blood Banks

a. Private Banks

b. Public Banking System

2. South/Central American Cord Blood Banks

a. Private Banks

b. Public Banking System

3. United Kingdom Cord Blood Banks

a. Private Banks

b. Public Banking System

4. European Cord Blood Banks

a. Private Banks

b. Public Banking System

5. Middle Eastern Cord Blood Banks

a. Private Banks

b. Public Banking System

6. Indian Cord Blood Banks

a. Private Banks

b. Public Banking System

7. Asian Cord Blood Banks

a. Private Banks

b. Public Banking System

8. Australian / New Zealand Cord Blood Banks

a. Private Australian and New Zealand Cord Blood Banks

b. Public Cord Blood Banks by Australian State

i. New South Wales

ii. Victoria

iii. Queensland

iv. Western Austalia, South Australia, & Tasmania

9. African Cord Blood Banks

a. Private Banks

b. Public Banking System

F. List of International Public Cord Blood Banks (Alphabetical by Country)

G. Worldwide List of AABB Accredited Cord Blood Facilities

V. United States Cord Blood Banking Legislation

A. U.S. State

B. U.S. Federal

1. Institute of Medicine Recommendations Study

a. Overview

b. Key Recommendations

c. IOM Study Shapes National Public Health Policy

2. Presidential Executive Order Expanding Approved Stem Cell Lines in Ethically Responsible Ways

a. Background

b. The Order

3. The Stem Cell Therapeutic and Research Act of 2005

a. Background

b. Current Status of the Act

VI. International Analysis – Trends, Policies and Industry Conditions (by Country)

A. NORTH & SOUTH  AMERICA

1. Canada

2. Mexico

3. United States

4. Brazil

5. Chile

6. Colombia

B. ASIA

1. China

2. Japan

3. Korea

4. Malaysia

5. Taiwan

6. Singapore

7. Thailand

C. INDIA

D. AUSTRALIA & NEW ZEALAND

E. EUROPE

1. European Union

a. Policy Overview

b. NETCORD Foundation

2. France

3. Germany & Austria

4. Italy

5. Netherlands

6. Spain

7. Poland

8. Russian Federation

9. United Kingdom

VII. Cost Analysis: Cord Blood Banking

A. Reasons for Variation in Cord Blood Pricing

1. Companies have Flexibility in the Pricing that they Set

2. Companies have Variables in the Services that they Offer

3. Variable Fee Breakdowns

B. Range of Pricing for U.S. Cord Blood Companies (1-100th percentiles)

1. U.S. Cord Blood Banking Price Range (1-100th%)

2. Lowest U.S. Pricing

3. Highest U.S. Pricing

4. Average U.S. Cord Blood Costs (25-75th percentiles)

5. Median Cost of U.S. Storage (50% percentile)

C. Range of Pricing for Canadian Cord Blood Companies (1-100th percentiles)

1. Canadian Cord Blood Banking Price Range (1-100th%)

2. Lowest Canadian Pricing

3. Highest Canadian. Pricing

4. Average Canadian. Cord Blood Costs (25-75th percentiles)

5. Median Cost of Canadian Storage (50% percentile)

VIII. Comparative Analysis of Quality Variables

A. Technical Variables

1. Vapor-Phase Storage vs. Liquid-Phase Storage

2. Cryo-bags vs. Cryo-vials

3. Pentastarch vs. Hetastarch

4. Computer Controlled vs. Manual Rate Freezing

5. Whole Sample vs. Volume Reduction

6. High-Control vs. Low-Control Aseptic Processing

B. Corporate Variables

1. Corporate Stability

2. Scientific Expertise

PART 2: EXPECTANT PARENTS, SURVEY RESULTS & FINDINGS

I. Survey Overview

A. Survey Population

B. Characterization of Market Survey Respondents

1. Geographic Distribution of Market Survey Respondents

2. Household Income Distribution of Survey Respondents

a. All Respondents

b. U.S. Respondents

3. Respondent Breakdown by Race

4. Respondent Breakdown by Gender

5. Respondent Breakdown by Level of Education

6. Respondent Breakdown by Location (City vs. Suburban vs. Rural)

7. Regional Breakdown of U.S. Respondents

8. Demographic Conclusions

II. Rates of Awareness: Unaware / Minimally Informed / Moderately Informed / Knowledgeable

A. Overall

B. By Gender

C. By Household Income

1. All Respondents

2. U.S. Respondents

D. By Education

E. By Race

F. By Geographic Location

1. Region within U.S.

2. Location (City vs. Suburban vs. Rural)

G. By Number of Existing Children within Family (e.g. Birth Order)

III. Factors Influencing Awareness

A. Personal Exposure: Relative Impact of Family, Co-Workers, Peers

B. Informational Sources: Information Sites, Books Medical Pamphlets, Government Sources

C. Medical Exposure: General Doctors, Ob / Gyn, Midwifes, Nurse, Other

D. Promotional Sources:  Internet Advertisements, Print Advertisements, Radio, TV, Other

IV. Factors Influencing Parental Decision-Making

A. Factors Influencing the Decision Not to Store Cord Blood

1.  Knowledge Level

2.  Price Sensitivity

3.  Safety Concerns

4.  Lack of Access

5.  Misconceptions

B. Factors Influencing the Decision for Private vs. Public Storage of Cord Blood

1. Ethical Beliefs

2. Gender

3. Total Household Income

4. Level of Education (Highest Level Achieved by at Least One Parent)

5. Race

6. Geographic Location

a. Region within U.S.

b. City vs. Suburban vs. Rural

7.  Access to Reliable Healthcare

8.  Number of Existing Children within Family (Birth Order)

9.  Source of Knowledge

10. Perceived Support of Medical Staff

11. Family Medical History

C. International Analysis of Cord Blood Banking Perceptions (Region-by-Region)

V. Parental Responsiveness to Health Statistics

A.  Overview

B.  Health Statistics

C.  Health Statistic Conclusions

VI. Parental Expectations

A. Quality of Services

B. Willingness to Educate/Inform

C. Reputability of Organization

VII. Trends

A. Rates of Cord Blood Storage (units per year)

B. Rates of Parental Awareness

C. Cord Blood Research Publication Rates

D. Cord Blood Research Funding Levels

E. Cord Blood Patent Breakdown

F.  Rates of Cord Blood Research Product Development

VIII. Informative Websites: Online Sources Utilized by Expectant Parents

A. Overview of Websites

1. Information Only

2. Commercial Affiliation

B. Dominant Regional Websites (International Analysis)

C. Most Important Criteria Used to Identify Sites to Inform Decision-Making

D. Underlying Reasons for Visiting Online Resources

IX. Conclusions

A. Traits of a “Model Customer”

1. “Model Customer” for a Private Cord Blood Bank

2. “Model Customer” for a Public Cord Blood Bank

B. Ideal Price Range

C. Approaches for Communicating with Expectant Parents

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Choices-in-Cord-Blood-Banking-Factors-Influencing-Parental-Decision-Making.html

The report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity. The report describes the current and projected patient population in obesity, detailing their incidence in the U.S., Europe, and Rest of World, and the clinical practices in obesity management encompassing surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy, and provides current and forecast of the market for these products in the U.S., Europe and Rest of World. The report profiles key companies in the market, detailing the current products, products in development, market position and overall businesses in obesity management.

Table of Contents:

Executive Summary

Section 1:        Clinical background
1.1       Body Mass Index
1.2       Growth of Obesity Worldwide
1.2.1          Prevalence of Obesity in the US Population
1.2.2          Obesity in the European Union
1.2.3          Japan’s Rising Obesity
1.2.4          Prevalence of Obesity in China
1.3       Why Treat Obesity?
1.4       Overweight, Obesity and Morbidity
1.4.1          The Multifactorial Causes of Obesity
1.4.1.1       Role of the Weight Regulatory System
1.4.1.1.1          Ghrelin
1.4.1.1.2          Peptide YY (PYY) & the Y2 receptor
1.4.1.2       Adipose Tissue
1.4.1.3       Abdominal Girth
1.4.1.4       Metabolic Syndrome
1.4.1.5       Obesity and Diabetes
1.4.1.6       Binge Eating Disorder (BED) and Surgery
1.4.2          Infectobesity:  Fat Viruses and Microbes?
1.4.3          Genetic Roots of Obesity
1.4.3.1       Fat as Survival Mechanism:  the Thrifty-Genotype
1.4.3.2       Leptin
1.4.3.3       Metabolic Liver Enzyme Defect
1.4.3.4       The Gene CD-38
1.4.3.5       The Gene FTO
1.4.4          The Obesogenic Picture:  Body & Environment
1.4.5          Patient Population Segmentation
1.4.5.1       The Elderly
1.4.5.2       Children and Adolescents

Section 2:        Weight Loss Management Approaches
2.1       Medically Supervised Diet, Behavior Modification and Nutritional Counseling Programs
2.1.1          Healthy Living Academies for Adolescents and Young Adults
2.1.2          Duke University’s Rice Dieta program
2.1.3          Medically Supervised Low Calorie and Very Low Calorie Diets (LCDs and VLCDs)
2.1.4          Behavior Modification Programs
2.2       Surgical Approaches
2.2.1          Restrictive Bariatric surgery
2.2.2          Malabsorptive Bariatric Surgery
2.2.3          Combination Restrictive-Malabsorptive bariatric surgery
2.2.4          Roux-en-Y gastric bypass surgery
2.2.5          Laparoscopic surgery
2.2.6          The Post-Op Period
2.2.7          Medical Device Implantation (Gastric Stimulation Device)
2.2.8          Gastric Balloon
2.2.9          Other Invasive Approaches Currently Under Development
2.2.9.1       Disabling the Vagus Nerve
2.2.9.2       Trans-Oral Stapling Device
2.3       Current Drug Developments
2.3.1          Cannabinoid (CB1) Receptor Agonists
2.3.2          Lipase Inhibitors
2.3.3          RNAi (RNA Interference)
2.3.4          Serotonin Receptor Agonists
2.3.5          Compounds Based on Intestinal Peptides

Section 3:        Impact of Obesity
3.1       Obesity Treatments, Related Costs and Reimbursement
3.1.1          Difficulty of Calculating Costs and Morbidity
3.1.2          Real Costs, Real Morbidity
3.2       Impact on Businesses/Economies
3.2.1          Increase in Workers’ Compensation Costs
3.3       Government Approaches to the Health Problem of Obesity
3.3.1          United States
3.3.1.1       The NIH:  a Strategic Plan for Obesity Research
3.3.1.2       Other US Agency Efforts
3.3.1.3       Changes in Medicare policy
3.3.1.4       “F as in Fat”
3.3.1.5       IRS and Deduction of Obesity Treatments
3.3.2          European Union
3.3.2.1       The ‘European Charter’ to Halt Obesity
3.3.2.2       The UK:  NHS, NICE and the Costs of Treating Obesity
3.3.2.3       SCOPE Internet-Based Physician Training
3.3.2.4       France:  the Caisse Nationale d’Assurance Maladie (CNAM)
3.3.3          Latin America & the Caribbean

Section 4:        Clinical Trends
4.1       Prevention and Intervention
4.2       Drug Developments
4.2.1          Utilizing Combinations of Drugs
4.2.2          CNS Versus Gastrointestinal Action
4.2.3          Stumble of CB1 Receptor Agonist Class
4.2.4          OTC alli
4.3       Tailoring the Strategy to the Patient
4.4       Bariatric Surgery
4.4.1          Gastric Bypass Versus Banding
4.4.2          Bariatric Surgery for Teens
4.4.3          Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS)

Section 5:        Products & Technologies
5.1       Medical Devices
5.1.1          Bariatric Surgery Devices in Use and Under Development
5.1.2          Restrictive Stomach Banding Devices
5.1.3          Restrictive Device Delivered Transorally
5.1.4          Gastric Stimulation Devices
5.1.5          Disabling the Vagus Nerve
5.1.6          Oral Device
5.2       Drug Development
5.2.1          CB-1 cannabinoid receptor agonists
5.2.2          Lipase inhibitors
5.2.3          RNAi
5.2.4          Serotonin receptor agonists
5.2.5          Intestinal peptide compounds
5.2.6          Ghrelin-based vaccine
5.3       Genetic Therapy

Section 6:        Market Assessment
6.1       Bariatric Surgery Devices
6.1.1          United States and Canada
6.1.1.1       Medicare Coverage Decision
6.1.1.2       US & Canada Market Shares
6.1.2          European Union
6.1.2.1       United Kingdom
6.1.2.2       France
6.1.2.3       Germany
6.1.2.4       Italy
6.1.2.5       Spain
6.1.2.6       Scandinavia
6.1.3          Rest of World
6.2       Pharmaceuticals
6.2.1          Rimonabant
6.2.2          PYY3-36
6.2.3          Pharmaceutical Market Assessment
6.2.3.1       United States & Canada
6.2.3.2       European Union & Scandinavia
6.2.3.2.1          United Kingdom
6.2.3.2.2          France
6.2.3.2.3          Germany
6.2.3.2.4          Italy
6.2.3.2.5          Spain
6.2.3.2.6          Scandinavia
6.2.3.3       Rest of World
6.3       Genetic Therapies
6.4       Obesity vaccines

Section 7:        Opportunities
7.1       Pharmaceutical Opportunities
7.2       Device Opportunities
7.2.1          Acquire or Partner with a Company with a Promising Device
7.2.2          Continue to Develop Devices for Treatment
7.2.3          Off-Label Uses of Current Devices
7.3       Market a Bundled Communication Package
7.4       Target the Market for Overweight & Obesity, Not Just Morbid Obesity
7.5       Working the Reimbursement Angle

Section 8:        Company Profiles
8.1     Abbott Laboratories
8.2     Alizyme plc
8.3     Allergan, Inc.
8.4     Amylin
8.5     Athersys, Inc.
8.6     Arena Pharmaceuticals
8.7     Bayer HealthCare
8.8     BioLineRx, Ltd.
8.9     Cousin Biotech SAS
8.10   Cyberonics
8.11   Cytos Biotechnology AG
8.12   EndoGastric Solutions
8.13   Ethicon Endo-Surgery
8.14   EnteroMedics
8.15   Genaera Corporation
8.16   GlaxoSmithKline
8.17   Ingenium Pharmaceuticals AG
8.18   IntraPace
8.19   Manhattan Pharmaceuticals, Inc.
8.20   Merck & Co., Inc.
8.21   Metabolic Pharmaceuticals
8.22   Millennium Pharmaceuticals
8.23   Nastech Pharmaceutical Company
8.24   Neurosearch AS
8.25   Oragenics
8.26   Orexigen Therapeutics
8.27   Peptimmune
8.28   Pfizer
8.29   Regeneron Pharmaceuticals
8.30   Roche
8.31   Sanofi-Aventis
8.32   Satiety, Inc.
8.33   Sirtris Pharmaceuticals
8.34   Speedel Pharmaceuticals
8.35   Thiakis Pharmaceuticals
8.36   Vitae Pharmaceuticals
8.37   Vivus, Inc.
8.38   Wyeth Pharmaceuticals
Appendix: List of Companies

List of Exhibits
Exhibit ES-1:  Selected Countries Ranked by Percentage of Overweight or Obese (BMI >25), 2006.
Exhibit ES-2:  Co-Morbidities Linked to Obesity
Exhibit ES-3:  Clinical Management of Obesity, Total World Revenue Market Forecast, 2004-2015 (US$M)
Exhibit 1-1:  Calculation of Body Mass Index (English or Metric)
Exhibit 1-2:  Selected Countries Ranked by Percentage of Population (Age 15+) Overweight or Obese, 2005
Exhibit 1-3:  Selected Countries Ranked by Percentage of Overweight or Obese (BMI >25), 2006
Exhibit 1-4:  WHO Graph of Mortality, Obesity (per 1 million people), Jan 2004
Exhibit 1-5:  USA:  Percentage of Children Ages 6–17 Who Are Overweight by Gender, and Race, and Hispanic Origin, 1976–1980 and 2003–2004
Exhibit 1-6:  Co-Morbidities Linked to Obesity
Exhibit 1-7:  Diagram of the Weight Regulatory Pathways
Exhibit 1-8:  Leptin’s Role in the Body
Exhibit 2-1: Current Market Status of Bariatric Surgery Medical Devices
Exhibit 2-2: Current Market Status of Pharmaceutical Treatments of Obesity
Exhibit 3-1:  Examples of Annual National Costs of Obesity (US$ Millions)
Exhibit 3-2:  A Selection of Federal Agencies and Their Involvement in Obesity Policy
Exhibit 5-1:  Bariatric Treatment Devices on Market and in Development
Exhibit 5-2:  Bariatric Device Company Market Shares, 2007
Exhibit 6-1:  Clinical Management of Obesity, Global Revenue Market Forecast, 2004-2015 (US$M)
Exhibit 6-2:  Clinical Management of Obesity, Total World Revenue Market Forecast, 2004-2015 (US$M)
Exhibit 6-3:  Clinical Management of Obesity, Global Pharmaceutical Revenue Market Share vs. Device Revenue Market Share, 2004-2015 (US$M)
Exhibit 6-4:  Bariatric Surgery Devices, Total World Revenue Market Forecast, 2004-2015 (US$M)
Exhibit 6-5:  Bariatric Surgery Devices, Total World Revenue Market Forecast, 2004-2015 (US$M)
Exhibit 6-6:  Bariatric Surgery Devices, Regional Share of Total World Revenues, 2004-2015 (US$M)
Exhibit 6-7:  Bariatric Surgery Devices, Market Forecast, United States and Canada, 2004-2015
Exhibit 6-8:  Bariatric Surgery Devices, Market Forecast, United States and Canada, 2004-2015
Exhibit 6-9:  Bariatric Surgery Devices, Market Shares, United States and Canada, 2015
Exhibit 6-10:  Bariatric Surgery Devices, Market Forecast, European Union, 2004-2015
Exhibit 6-11:  Bariatric Surgery Devices, Revenue Forecast, European Union, 2004-2015
Exhibit 6-12:  Bariatric Surgery Device Revenues by Country Share, EU & Scandinavia, 2007
Exhibit 6-13:  Bariatric Surgery Device Revenues by Country Share, EU & Scandinavia, 2015
Exhibit 6-14:  Bariatric Surgery Device Market, United Kingdom, 2004-2015
Exhibit 6-15:  Bariatric Surgery Device Market, United Kingdom, 2004-2015
Exhibit 6-16:  Bariatric Surgery Device Market, France, 2004-2015
Exhibit 6-17:  Bariatric Surgery Device Market, France, 2004-2015
Exhibit 6-18:  Bariatric Surgery Device Company Market Shares, France, 2007
Exhibit 6-19:  Bariatric Surgery Device Market, Germany, 2004-2015
Exhibit 6-20:  Bariatric Surgery Device Market, Germany, 2004-2015
Exhibit 6-21:  Bariatric Surgery Device Company Market Shares, Germany, 2007
Exhibit 6-22:  Bariatric Surgery Device Market, Italy, 2004-2015
Exhibit 6-23:  Bariatric Surgery Device Market, Italy, 2004-2015
Exhibit 6-24:  Bariatric Surgery Device Company Market Shares, Italy, 2007
Exhibit 6-25:  Bariatric Surgery Device Market, Spain, 2004-2015
Exhibit 6-26:  Bariatric Surgery Device Market, Spain, 2004-2015
Exhibit 6-27:  Bariatric Surgery Device Company Market Shares, Spain, 2007
Exhibit 6-28:  Bariatric Surgery Device Market, Scandinavia, 2004-2015
Exhibit 6-29:  Bariatric Surgery Device Market, Scandinavia, 2004-2015
Exhibit 6-30:  Bariatric Surgery Device Market, Rest of World, 2004-2015
Exhibit 6-31:  Bariatric Surgery Device Market, Rest of World, 2004-2015
Exhibit 6-32:  Pipeline of Selected Anorectic Pharmaceuticals, 2007
Exhibit 6-33:  Global Anorectic Pharmaceutical Market, 2004-2015
Exhibit 6-34:  Global Anorectic Pharmaceutical Market, 2004-2015
Exhibit 6-35:  Anorectic Pharmaceutical Market, USA & Canada, 2004-2015
Exhibit 6-36:  Anorectic Pharmaceutical Market, USA & Canada, 2004-2015
Exhibit 6-37:  Anorectic Pharmaceutical Market, EU & Scandinavia, 2004-2015
Exhibit 6-38:  Anorectic Pharmaceutical Market, EU & Scandinavia, 2004-2015
Exhibit 6-39:  Anorectic Pharmaceutical Market, United Kingdom, 2004-2015
Exhibit 6-40:  Anorectic Pharmaceutical Market, United Kingdom, 2004-2015
Exhibit 6-41:  Anorectic Pharmaceutical Market, France, 2004-2015
Exhibit 6-42:  Anorectic Pharmaceutical Market, France, 2004-2015
Exhibit 6-43:  Anorectic Pharmaceutical Market, Germany, 2004-2015
Exhibit 6-44:  Anorectic Pharmaceutical Market, Germany, 2004-2015
Exhibit 6-45:  Anorectic Pharmaceutical Market, Italy, 2004-2015
Exhibit 6-46:  Anorectic Pharmaceutical Market, Italy, 2004-2015
Exhibit 6-47:  Anorectic Pharmaceutical Market, Spain, 2004-2015
Exhibit 6-48:  Anorectic Pharmaceutical Market, Spain, 2004-2015
Exhibit 6-49:  Anorectic Pharmaceutical Market, Scandinavia, 2004-2015
Exhibit 6-50:  Anorectic Pharmaceutical Market, Scandinavia, 2004-2015
Exhibit 6-51:  Anorectic Pharmaceutical Market, ROW, 2004-2015
Exhibit 6-52:  Anorectic Pharmaceutical Market, ROW, 2004-2015
Exhibit 7-1:  Company Alliance Options

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Worldwide-Market-for-the-Clinical-Management-of-Obesity-2007-2015.html

Apoptosis is regarded as the major mode of cell death in cancer and should therefore be considered as a potential target when developing new antineoplastic drugs. An increasing number of companies are doing so, and we anticipate that this approach will pay substantial dividends, both therapeutically and commercially.

This report reviews 370 apoptosis-modulating drug candidates (9% in Phase 3 or later) developed by 233 companies and having 148 molecular targets. The report reveals a transforming market offering growth potential in cancer and other indications. Apoptosis (programmed cell death) is a natural phenomenon and occurs via a tightly regulated complex signaling cascade. Several major classes of drugs on the market - cancer chemotherapeutics, anti-TNF therapies, glucocorticoids - are now known to work, at least partly and/or indirectly, via apoptosis modulation. In cancer and in other diseases, elements of the apoptotic process become dysregulated, offering many direct targets for drug discovery.

This report reveals that many drugs have been reported to induce cancer cell apoptosis in preclinical studies. Traditional chemotherapeutic agents impair cell division and induce apoptosis indirectly. Many of the second generation indirect apoptogens (IAs) in development are biotherapies. They include: monoclonal antibodies, peptides, oligonucleotides, oncolytic viruses, and immunotherapies. The prevalence of indirect apoptotic effects emphasises the importance of screening for apoptotic potential in new anticancer drugs. This is being enabled by the increasing availability of biomarker-based assays of apoptosis.

Cancer is characterized by the (at least) partial suppression of apoptosis, which in turn causes chemotherapy resistance. Of particular interest therefore are direct apoptogens (DAs) designed to overcome treatment resistance due to overexpression of anti-apoptotic genes or downregulation of pro-apoptotic genes. Over one hundred first-in-class DAs directed at one or more of over 40 genes with a direct involvement in apoptosis (identified using the Stanford Research Institute’s PANTHER database) are analyzed in this report. The targets include caspases, BCL2 family members, and TP53 (p53). Other targets which are gaining recognition are the proteasome and heat shock proteins (HSPs). Millenium Pharmaceuticals’ Velcade is the first proteasome inhibitor (PI) on the US market, and represents the most cancer cell-selective apoptogen approved to date.

We forecast that the market for specific, direct, modulators of apoptosis in oncology will grow from $0.6 billion in 2008 to $12 billion in 2013, an average annual growth rate (AGR) of 64%, when it will represent about 22% of all oncology drug sales. This is well in excess of the AGR for oncology as a whole (which is expected to be almost 14% over the same period). Oncology will itself be the best performing major segment of the overall pharmaceutical market, which will grow at around 6% over the forecast period. Individual forecasts are presented for PIs and other DAs targeting caspases, BCL2 proteins, TP53, and HSPs.

We estimate that indirect modulators of apoptosis (which have varying apoptotic effects, but do not target known apoptotic pathways) comprise around half the oncology market by sales volume and will perform similarly to it, rising from $28 billion in 2008 to $57 billion in 2013, an average AGR of 12%. This corresponds to a fairly constant market share (51% of the oncology market in 2008, falling slightly to 48% by 2013). Forecasts are presented for first generation IAs and for the two main groups of second generation IAs (biologics and small moecules such as kinase inhibitors and hormone antagonists).

Various agents known or suspected to have apoptosis-modulating properties are also in development for indications other than cancer. The two main areas are: CNS disorders (in particular neurodegenerative diseases) and chronic inflammation/autoimmunity (in particular rheumatoid arthritis). Depending on cells being targeted, therapies seek to either promote or interfere with apoptosis. Some of the DAs currently in development for cancer may also find application in the treatment of other diseases.

This report also examines apoptosis-related patents and patent applications filed during the current decade to identify the most prolific filers of patents, technology trends and potential therapeutic applications of apoptosis research.

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Apoptosis-2009-Opportunities-in-Cancer-and-Other-Diseases.html

Worldwide Market for the Clinical Management of Obesity, 2007-2015

The report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity. The report describes the current and projected patient population in obesity, detailing their incidence in the U.S., Europe, and Rest of World, and the clinical practices in obesity management encompassing surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy, and provides current and forecast of the market for these products in the U.S., Europe and Rest of World. The report profiles key companies in the market, detailing the current products, products in development, market position and overall businesses in obesity management.

Table of Contents:

Executive Summary

Section 1:        Clinical background
1.1       Body Mass Index
1.2       Growth of Obesity Worldwide
1.2.1          Prevalence of Obesity in the US Population
1.2.2          Obesity in the European Union
1.2.3          Japan’s Rising Obesity
1.2.4          Prevalence of Obesity in China
1.3       Why Treat Obesity?
1.4       Overweight, Obesity and Morbidity
1.4.1          The Multifactorial Causes of Obesity
1.4.1.1       Role of the Weight Regulatory System
1.4.1.1.1          Ghrelin
1.4.1.1.2          Peptide YY (PYY) & the Y2 receptor
1.4.1.2       Adipose Tissue
1.4.1.3       Abdominal Girth
1.4.1.4       Metabolic Syndrome
1.4.1.5       Obesity and Diabetes
1.4.1.6       Binge Eating Disorder (BED) and Surgery
1.4.2          Infectobesity:  Fat Viruses and Microbes?
1.4.3          Genetic Roots of Obesity
1.4.3.1       Fat as Survival Mechanism:  the Thrifty-Genotype
1.4.3.2       Leptin
1.4.3.3       Metabolic Liver Enzyme Defect
1.4.3.4       The Gene CD-38
1.4.3.5       The Gene FTO
1.4.4          The Obesogenic Picture:  Body & Environment
1.4.5          Patient Population Segmentation
1.4.5.1       The Elderly
1.4.5.2       Children and Adolescents

Section 2:        Weight Loss Management Approaches
2.1       Medically Supervised Diet, Behavior Modification and Nutritional Counseling Programs
2.1.1          Healthy Living Academies for Adolescents and Young Adults
2.1.2          Duke University’s Rice Dieta program
2.1.3          Medically Supervised Low Calorie and Very Low Calorie Diets (LCDs and VLCDs)
2.1.4          Behavior Modification Programs
2.2       Surgical Approaches
2.2.1          Restrictive Bariatric surgery
2.2.2          Malabsorptive Bariatric Surgery
2.2.3          Combination Restrictive-Malabsorptive bariatric surgery
2.2.4          Roux-en-Y gastric bypass surgery
2.2.5          Laparoscopic surgery
2.2.6          The Post-Op Period
2.2.7          Medical Device Implantation (Gastric Stimulation Device)
2.2.8          Gastric Balloon
2.2.9          Other Invasive Approaches Currently Under Development
2.2.9.1       Disabling the Vagus Nerve
2.2.9.2       Trans-Oral Stapling Device
2.3       Current Drug Developments
2.3.1          Cannabinoid (CB1) Receptor Agonists
2.3.2          Lipase Inhibitors
2.3.3          RNAi (RNA Interference)
2.3.4          Serotonin Receptor Agonists
2.3.5          Compounds Based on Intestinal Peptides

Section 3:        Impact of Obesity
3.1       Obesity Treatments, Related Costs and Reimbursement
3.1.1          Difficulty of Calculating Costs and Morbidity
3.1.2          Real Costs, Real Morbidity
3.2       Impact on Businesses/Economies
3.2.1          Increase in Workers’ Compensation Costs
3.3       Government Approaches to the Health Problem of Obesity
3.3.1          United States
3.3.1.1       The NIH:  a Strategic Plan for Obesity Research
3.3.1.2       Other US Agency Efforts
3.3.1.3       Changes in Medicare policy
3.3.1.4       “F as in Fat”
3.3.1.5       IRS and Deduction of Obesity Treatments
3.3.2          European Union
3.3.2.1       The ‘European Charter’ to Halt Obesity
3.3.2.2       The UK:  NHS, NICE and the Costs of Treating Obesity
3.3.2.3       SCOPE Internet-Based Physician Training
3.3.2.4       France:  the Caisse Nationale d’Assurance Maladie (CNAM)
3.3.3          Latin America & the Caribbean

Section 4:        Clinical Trends
4.1       Prevention and Intervention
4.2       Drug Developments
4.2.1          Utilizing Combinations of Drugs
4.2.2          CNS Versus Gastrointestinal Action
4.2.3          Stumble of CB1 Receptor Agonist Class
4.2.4          OTC alli
4.3       Tailoring the Strategy to the Patient
4.4       Bariatric Surgery
4.4.1          Gastric Bypass Versus Banding
4.4.2          Bariatric Surgery for Teens
4.4.3          Teen-Longitudinal Assessment of Bariatric Surgery (Teen-LABS)

Section 5:        Products & Technologies
5.1       Medical Devices
5.1.1          Bariatric Surgery Devices in Use and Under Development
5.1.2          Restrictive Stomach Banding Devices
5.1.3          Restrictive Device Delivered Transorally
5.1.4          Gastric Stimulation Devices
5.1.5          Disabling the Vagus Nerve
5.1.6          Oral Device
5.2       Drug Development
5.2.1          CB-1 cannabinoid receptor agonists
5.2.2          Lipase inhibitors
5.2.3          RNAi
5.2.4          Serotonin receptor agonists
5.2.5          Intestinal peptide compounds
5.2.6          Ghrelin-based vaccine
5.3       Genetic Therapy

Section 6:        Market Assessment
6.1       Bariatric Surgery Devices
6.1.1          United States and Canada
6.1.1.1       Medicare Coverage Decision
6.1.1.2       US & Canada Market Shares
6.1.2          European Union
6.1.2.1       United Kingdom
6.1.2.2       France
6.1.2.3       Germany
6.1.2.4       Italy
6.1.2.5       Spain
6.1.2.6       Scandinavia
6.1.3          Rest of World
6.2       Pharmaceuticals
6.2.1          Rimonabant
6.2.2          PYY3-36
6.2.3          Pharmaceutical Market Assessment
6.2.3.1       United States & Canada
6.2.3.2       European Union & Scandinavia
6.2.3.2.1          United Kingdom
6.2.3.2.2          France
6.2.3.2.3          Germany
6.2.3.2.4          Italy
6.2.3.2.5          Spain
6.2.3.2.6          Scandinavia
6.2.3.3       Rest of World
6.3       Genetic Therapies
6.4       Obesity vaccines

Section 7:        Opportunities
7.1       Pharmaceutical Opportunities
7.2       Device Opportunities
7.2.1          Acquire or Partner with a Company with a Promising Device
7.2.2          Continue to Develop Devices for Treatment
7.2.3          Off-Label Uses of Current Devices
7.3       Market a Bundled Communication Package
7.4       Target the Market for Overweight & Obesity, Not Just Morbid Obesity
7.5       Working the Reimbursement Angle

Section 8:        Company Profiles
8.1     Abbott Laboratories
8.2     Alizyme plc
8.3     Allergan, Inc.
8.4     Amylin
8.5     Athersys, Inc.
8.6     Arena Pharmaceuticals
8.7     Bayer HealthCare
8.8     BioLineRx, Ltd.
8.9     Cousin Biotech SAS
8.10   Cyberonics
8.11   Cytos Biotechnology AG
8.12   EndoGastric Solutions
8.13   Ethicon Endo-Surgery
8.14   EnteroMedics
8.15   Genaera Corporation
8.16   GlaxoSmithKline
8.17   Ingenium Pharmaceuticals AG
8.18   IntraPace
8.19   Manhattan Pharmaceuticals, Inc.
8.20   Merck & Co., Inc.
8.21   Metabolic Pharmaceuticals
8.22   Millennium Pharmaceuticals
8.23   Nastech Pharmaceutical Company
8.24   Neurosearch AS
8.25   Oragenics
8.26   Orexigen Therapeutics
8.27   Peptimmune
8.28   Pfizer
8.29   Regeneron Pharmaceuticals
8.30   Roche
8.31   Sanofi-Aventis
8.32   Satiety, Inc.
8.33   Sirtris Pharmaceuticals
8.34   Speedel Pharmaceuticals
8.35   Thiakis Pharmaceuticals
8.36   Vitae Pharmaceuticals
8.37   Vivus, Inc.
8.38   Wyeth Pharmaceuticals
Appendix: List of Companies

List of Exhibits
Exhibit ES-1:  Selected Countries Ranked by Percentage of Overweight or Obese (BMI >25), 2006.
Exhibit ES-2:  Co-Morbidities Linked to Obesity
Exhibit ES-3:  Clinical Management of Obesity, Total World Revenue Market Forecast, 2004-2015 (US$M)
Exhibit 1-1:  Calculation of Body Mass Index (English or Metric)
Exhibit 1-2:  Selected Countries Ranked by Percentage of Population (Age 15+) Overweight or Obese, 2005
Exhibit 1-3:  Selected Countries Ranked by Percentage of Overweight or Obese (BMI >25), 2006
Exhibit 1-4:  WHO Graph of Mortality, Obesity (per 1 million people), Jan 2004
Exhibit 1-5:  USA:  Percentage of Children Ages 6–17 Who Are Overweight by Gender, and Race, and Hispanic Origin, 1976–1980 and 2003–2004
Exhibit 1-6:  Co-Morbidities Linked to Obesity
Exhibit 1-7:  Diagram of the Weight Regulatory Pathways
Exhibit 1-8:  Leptin’s Role in the Body
Exhibit 2-1: Current Market Status of Bariatric Surgery Medical Devices
Exhibit 2-2: Current Market Status of Pharmaceutical Treatments of Obesity
Exhibit 3-1:  Examples of Annual National Costs of Obesity (US$ Millions)
Exhibit 3-2:  A Selection of Federal Agencies and Their Involvement in Obesity Policy
Exhibit 5-1:  Bariatric Treatment Devices on Market and in Development
Exhibit 5-2:  Bariatric Device Company Market Shares, 2007
Exhibit 6-1:  Clinical Management of Obesity, Global Revenue Market Forecast, 2004-2015 (US$M)
Exhibit 6-2:  Clinical Management of Obesity, Total World Revenue Market Forecast, 2004-2015 (US$M)
Exhibit 6-3:  Clinical Management of Obesity, Global Pharmaceutical Revenue Market Share vs. Device Revenue Market Share, 2004-2015 (US$M)
Exhibit 6-4:  Bariatric Surgery Devices, Total World Revenue Market Forecast, 2004-2015 (US$M)
Exhibit 6-5:  Bariatric Surgery Devices, Total World Revenue Market Forecast, 2004-2015 (US$M)
Exhibit 6-6:  Bariatric Surgery Devices, Regional Share of Total World Revenues, 2004-2015 (US$M)
Exhibit 6-7:  Bariatric Surgery Devices, Market Forecast, United States and Canada, 2004-2015
Exhibit 6-8:  Bariatric Surgery Devices, Market Forecast, United States and Canada, 2004-2015
Exhibit 6-9:  Bariatric Surgery Devices, Market Shares, United States and Canada, 2015
Exhibit 6-10:  Bariatric Surgery Devices, Market Forecast, European Union, 2004-2015
Exhibit 6-11:  Bariatric Surgery Devices, Revenue Forecast, European Union, 2004-2015
Exhibit 6-12:  Bariatric Surgery Device Revenues by Country Share, EU & Scandinavia, 2007
Exhibit 6-13:  Bariatric Surgery Device Revenues by Country Share, EU & Scandinavia, 2015
Exhibit 6-14:  Bariatric Surgery Device Market, United Kingdom, 2004-2015
Exhibit 6-15:  Bariatric Surgery Device Market, United Kingdom, 2004-2015
Exhibit 6-16:  Bariatric Surgery Device Market, France, 2004-2015
Exhibit 6-17:  Bariatric Surgery Device Market, France, 2004-2015
Exhibit 6-18:  Bariatric Surgery Device Company Market Shares, France, 2007
Exhibit 6-19:  Bariatric Surgery Device Market, Germany, 2004-2015
Exhibit 6-20:  Bariatric Surgery Device Market, Germany, 2004-2015
Exhibit 6-21:  Bariatric Surgery Device Company Market Shares, Germany, 2007
Exhibit 6-22:  Bariatric Surgery Device Market, Italy, 2004-2015
Exhibit 6-23:  Bariatric Surgery Device Market, Italy, 2004-2015
Exhibit 6-24:  Bariatric Surgery Device Company Market Shares, Italy, 2007
Exhibit 6-25:  Bariatric Surgery Device Market, Spain, 2004-2015
Exhibit 6-26:  Bariatric Surgery Device Market, Spain, 2004-2015
Exhibit 6-27:  Bariatric Surgery Device Company Market Shares, Spain, 2007
Exhibit 6-28:  Bariatric Surgery Device Market, Scandinavia, 2004-2015
Exhibit 6-29:  Bariatric Surgery Device Market, Scandinavia, 2004-2015
Exhibit 6-30:  Bariatric Surgery Device Market, Rest of World, 2004-2015
Exhibit 6-31:  Bariatric Surgery Device Market, Rest of World, 2004-2015
Exhibit 6-32:  Pipeline of Selected Anorectic Pharmaceuticals, 2007
Exhibit 6-33:  Global Anorectic Pharmaceutical Market, 2004-2015
Exhibit 6-34:  Global Anorectic Pharmaceutical Market, 2004-2015
Exhibit 6-35:  Anorectic Pharmaceutical Market, USA & Canada, 2004-2015
Exhibit 6-36:  Anorectic Pharmaceutical Market, USA & Canada, 2004-2015
Exhibit 6-37:  Anorectic Pharmaceutical Market, EU & Scandinavia, 2004-2015
Exhibit 6-38:  Anorectic Pharmaceutical Market, EU & Scandinavia, 2004-2015
Exhibit 6-39:  Anorectic Pharmaceutical Market, United Kingdom, 2004-2015
Exhibit 6-40:  Anorectic Pharmaceutical Market, United Kingdom, 2004-2015
Exhibit 6-41:  Anorectic Pharmaceutical Market, France, 2004-2015
Exhibit 6-42:  Anorectic Pharmaceutical Market, France, 2004-2015
Exhibit 6-43:  Anorectic Pharmaceutical Market, Germany, 2004-2015
Exhibit 6-44:  Anorectic Pharmaceutical Market, Germany, 2004-2015
Exhibit 6-45:  Anorectic Pharmaceutical Market, Italy, 2004-2015
Exhibit 6-46:  Anorectic Pharmaceutical Market, Italy, 2004-2015
Exhibit 6-47:  Anorectic Pharmaceutical Market, Spain, 2004-2015
Exhibit 6-48:  Anorectic Pharmaceutical Market, Spain, 2004-2015
Exhibit 6-49:  Anorectic Pharmaceutical Market, Scandinavia, 2004-2015
Exhibit 6-50:  Anorectic Pharmaceutical Market, Scandinavia, 2004-2015
Exhibit 6-51:  Anorectic Pharmaceutical Market, ROW, 2004-2015
Exhibit 6-52:  Anorectic Pharmaceutical Market, ROW, 2004-2015
Exhibit 7-1:  Company Alliance Options

For more please visit
http://www.bharatbook.com/Market-Research-Reports/Worldwide-Market-for-the-Clinical-Management-of-Obesity-2007-2015.html

Booming Clinical Trials Market in India

The clinical trial market in India looks very lucrative. The country promises to be one of the hottest destinations for conducting global clinical trials, owing to a huge patient pool representing both chronic and infectious diseases, easy recruitment of patients, and high cost savings. Moreover, the market is getting boost from improved IPR protection with changed rules and also from reduced taxes and duties.

According to our new research study on the sector called “Booming Clinical Trials Market in India”, the clinical trial outsourced market in India is forecasted to grow at a CAGR of around 31% during 2010-2012. Presently, the market is characterized by the dominance of phase III and phase II trials, which currently hold more than 80% of the market. This scenario is expected to remain intact in future as well. In terms of competitive landscape, the market is characterized by many small CROs, with certain companies like Syngene, Quintiles, Lambda therapeutics, Vimta labs doing better in comparison of the rest.

Our report has found that one of the biggest reasons attracting drug manufacturers and CROs to India is the country’s vast patient pool. The number of patients for chronic and infectious ailments in India surpasses that of nearly any other country. Moreover, clinical trials for drugs related to central nervous system and cancer have been mainly outsourced to India in recent years. Backed by this factor, the number of clinical studies in India is expected to grow at a CAGR of over 14% during the forecast period. In this regard, the report provides rational analysis of the factors which are supporting the forecast.

Our report provides extensive information on the clinical trial market in India, with detailed description of the regulatory environment and cost factors promoting the market. It also highlights several emerging market trends like clinical data management, pathology and diagnostic market, etc. The research study offers detailed statistical and analytical review on demographics, macroeconomic indicators, disease profile, clinical service market, key drivers and restraints. It contains all the requisite information that will help clients to draw up market strategies and assess opportunity areas in India’s clinical trial market.

Table of Contents:

1. Analyst View
2. Clinical Trials Market Overview
2.1 Global Clinical Research Market
2.2 Clinical Research Market in Asia-Pacific
2.3 Clinical Research Market in India
2.3.1 Number of Clinical Trials
2.3.2 Clinical Trials by Type
2.3.3 Clinical Research Market
2.3.4 Patient Participation
2.3.5 Market Trends
3. Size and Patient Pool Availability
3.1 Population and Demographics
3.2 Disease Profile
3.3 Patient Availability and Recruitment
4. Infrastructure and Expertise
4.1 Education
4.2 Clinical Research Professionals
4.3 Hospital Beds
4.4 ICH/GCP Compliant Sites
5. Cost Analysis
5.1 Phase I Clinical Trials
5.1.1 Cost of Staff
5.1.2 Cost of Utility
5.2 Phase II Clinical Trials
5.2.1 Cost of Infrastructure and Staff
5.2.2 Cost of Utility
5.3 Phase III Clinical Trials
5.3.1 Cost of Infrastructure and Staff
5.3.2 Cost of Utility
5.4 Phase IV Clinical Trials
5.4.1 Cost of Infrastructure and Staff
5.4.2 Cost of Utility
6. Success and Risk Factor Analysis
6.1 Lower Cost
6.2 Faster Completion
6.3 Pathology and Diagnostic Market
6.4 Clinical Data Management
6.5 Increasing Competition between Developing Countries
6.6 Demand-Supply Gap of Clinical Professionals
6.7 Long Time for Approval
7. Regulatory Environment
7.1 The Institutional Ethics Committee (IEC)
7.2 Trials that can/cannot be Conducted in India
7.3 Clinical Trials Registry
7.4 Intellectual Property Protection
7.5 Incentives Given by the Government
8. RNCOS Recommendations
9. Key Players
9.1 Syngene International Ltd
9.2 Quintiles Research (India) Private Limited
9.3 Lambda Therapeutic Research Ltd
9.4 Bioserve Clinical Research Pvt. Ltd.
9.5 Veeda Clinical Research
9.6 IGATE Clinical Research International
9.7 PharmaNet
9.8 Vimta Labs

List of Figures

Figure 2-1: Global - Number of Clinical Trials (2007-2009)
Figure 2-2: Global - Clinical Research Market (Billion US$), 2007-2009
Figure 2-3: Global - Forecast for Clinical Research Market (Billion US$), 2010-2012
Figure 2-4: Global - Clinical Research Market by Phase (%), 2008
Figure 2-5: Asia-Pacific - Share of Countries in Clinical Trial Studies (2008)
Figure 2-6: Number of Clinical Trials (2007-2009)
Figure 2-7: Forecast for Number of Clinical Trials (2010-2012)
Figure 2-8: Clinical Trials by Phase (%)
Figure 2-9: Clinical Trials by Therapy (%)
Figure 2-10: Clinical Research Market (Million US$), 2007-2009
Figure 2-11: Forecast for Clinical Research Market (Million US$), 2010-2012
Figure 2-12: Forecast for Number of Patients Participating in Clinical Trials (Million), 2010-2012
Figure 2-13: Pharma Outsourcing Market (Billion US$), 2007-2009
Figure 2-14: Pharma Outsourcing Market by Segment (%), 2008
Figure 3-1: Population (Million), 2006-2009
Figure 3-2: Forecast for Population (Million), 2010-2012
Figure 3-3: Population Breakup by Age Group (%), 2006-2009
Figure 3-4: Forecast for Population Breakup by Age Group (%), 2010-2012
Figure 3-5: Various Causes of Death (%), 2008
Figure 3-6: Forecast for Various Causes of Death (%), 2030
Figure 3-7: New and Total Number of Cancer Patients (‘000)
Figure 3-8: Number of Hypertension Patients (Million), 2000, 2007 & 2025
Figure 3-9: Number of Coronary Heart Patients (Million), 2005 & 2015
Figure 3-10: Recruitment Time for Patients Participating in Clinical Trials in Comparison to US (Days)
Figure 3-11: Number of Patient per Site in Comparison to US
Figure 4-1: Number of Individuals with Bachelor and Higher Degree (Million), 1991, 2004, 2006 & 2008
Figure 4-2: Number of Graduates and Postgraduates (Million), 2004
Figure 4-3: Share of Science Doctorates in Total Doctorates (2004)
Figure 4-4: Number of Doctors in Comparison to US and Germany (‘000), 2008
Figure 4-5: Number of Doctors (‘000), 2007-2009
Figure 4-6: Forecast for Number of Doctors (‘000), 2010-2012
Figure 4-7: Number of GCP Trained Investigators (2002 & 2005)
Figure 4-8: Number of GCP Trained Investigators in Comparison to US
Figure 4-9: Number of Hospital Beds (‘000), 2007-2009
Figure 4-10: Number of Hospital Beds in Comparison to UK, US and Germany (‘000), 2008
Figure 4-11: Forecast for Number of Hospital Beds (‘000), 2010-2012
Figure 4-12: Number of Sites for Clinical Trials in Comparison to UK, US and Germany
Figure 5-1: Average Cost per Patient for Conducting Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-2: Average Cost per Patient for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-3: Average Cost per Patient for Conducting Phase II Clinical Trials in comparison to UK, US and Germany (US$)
Figure 5-4: Annual Cost of Office Space for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-5: Average Cost per Patient for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-6: Annual Cost of Office Space for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-7: Average Cost per Patient for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 5-8: Annual Cost of Office Space for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Figure 6-1: Average Cost for Conducting Various Clinical Trial Phases in Comparison to US
Figure 6-2: Time Taken for Conducting Clinical Trials by Phase in Comparison to US (Months)
Figure 6-3: Numbers of Clinical Trials Completed on Time in Comparison to UK, US and Germany
Figure 6-4: IVD Market (Million US$), 2008 & 2012
Figure 6-5: Average Time for Approval of Clinical Trials in Comparison to UK, US and Germany (Weeks)
Figure 9-1: Share of Players in Bio-services Market (2008)

List of Tables:

Table 3-1: Number of Deaths due to Various Causes (2005)
Table 3-2: Number of Diabetic Patients in Age Group 20-79 (‘000), 2007
Table 3-3: Forecast for Number of Diabetic Patients in Age Group 20-79 (‘000), 2025
Table 3-4: New Cancers Incidences (per ‘00,000 Females), 2005
Table 3-5: New Cancers Incidences (per ‘00,000 Males), 2005
Table 3-6: Prevalence of Overweight & Obesity in Males and Females (%), 2005 & 2015
Table 4-1: Structure of Medical Education
Table 4-2: Number of GLA Approved Facilities by Type
Table 5-1: Annual Cost of Staff for Conducting Phase I Clinical Trials in comparison to UK, US and Germany (US$)
Table 5-2: Annual Cost of Utility for Conducting Phase I Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-3: Annual Cost of Staff for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-4: Annual Cost of Utility for Conducting Phase II Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-5: Annual Cost of Staff for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-6: Annual Cost of Utility for Conducting Phase III Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-7: Annual Cost of Staff for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Table 5-8: Annual Cost of Utility for Conducting Phase IV Clinical Trials in Comparison to UK, US and Germany (US$)
Table 8-1: Comparison of Factors Affecting Clinical Trials Market among Different Countries

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Booming-Clinical-Trials-Market-in-India.html

Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reach 4-5 days post fertilization. hESCs are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body.

hESCs were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research.

Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. Of particular interest to the medical community is the potential for use of hESCs to heal tissues with naturally limited capacity for renewal, such as the human heart, liver and brain.

This market report recognizes that a wide range of products and services are needed to support this active and well-funded research community. Thus, this report provides:

* Discussion of key advances in hESC research
* A breakdown of hESC research applications, including shared priorities and priorities by segment
* hESC patent analysis
* Historical and future growth projections for the hESC market
* Competitive analysis of providers of hESC research tools
* Overview of specialty pharma companies developing hESC therapies
* Overview of toxicology testing legislation impacting use of hESC in toxicology applications
* A breakdown of hESC research product categories
* Suggestions for novel NSC research products, including cells, kits, assays, media and reagents
* Guidance for companies that wish to offer hESCs products
* And more…

Table of Contents:

I. Background

A. Human Embryonic Stem Cells (hESC)
B. Brief History
C. Use in Treatment of Disease
D. Human Embryonic Stem Cell Line Availability

II. Available Stem Cell Lines

A. NIH Registry Approved
B. Sources of Additional Published hESC Lines
C. Sources of Additional Unpublished hESC Lines

III. Applications

A. Basic Stem Cell Biology
B. Cellular Therapies

1. Overview
2. Heart Regeneration
3. Pancreatic Islet Cell Replacement
4. Neural Regeneration

C. Tissue Engineering
D. Toxicology Testing

IV. Application Priorities

A. Overall

1. Cell-Based Therapies: Greatest shared priority across research community

a. Beneficial hESC Characteristics
b. hESC Safety Concerns
c. hESC Characterization in Vitro
d. hESC Characterization in Vivo

2. Toxicology Assessment: Another area of huge potential

a. Overview
b. Commercial Interest

B. By Segment

1. Academic
2. Biotech
3. Pharma

V. Patents

A. Key U.S. Neuronal Stem and Progenitor Cell Patents

B. Additional Key U.S. Patents

1. Geron Corporation
2. Regents of the University of California
3. BresaGen Inc.
4. Regeneron Pharmaceuticals, Inc.
5. Vanderbuilt University

C. Additional Key European Patents

1. ES Cell International PTE Ltd.
2. DNAVEC Research Inc.
3. University of Edinburgh

VI. Historical and Future Growth Projections

A. PubMed Analysis

1. Historical Analysis (Trailing 10 Years)
2. Future Growth Predictions (5-Year Forecasts)
3. Breakdown of ESC Research by Species

B. CRISP Analysis
C. Patent Analysis

1. All Fields
2. Abstract Only

VII. hESC PRODUCT COMPETITORS

A. Cellartis AB

1. Human embryonic stem cell lines
2. Monoclonal Antibodies for hESC Research
3. Differentiated Cell Products
4. Associated hESC products

B. Vitrolife

C. Tataa Biocenter

D. Invitrogen

1. hESC Culture Media & Reagents
2. hESC-qualified Basement Membrane Extract
3. hESC cDNA Libraries
4. hESC Reporter Cells
5. hESC PCR Kits
6. hESC Stem Cell Antibodies
7. hESC Stem Cell Growth Factors

E. Stem Cell Technologies

1. hESC Culture Media & Reagents
2. hESC Primary & Secondary Antibodies

F. BD Biosciences

G. Chemicon

1. hESC Culture Media and Reagents
2. hESC Lines
3. hESC Kits
4. hESC Antibodies

H. R&D Systems

I. SA Biosciences

J. Thermo Scientific

K. Australian Stem Cell Centre

VIII. Specialty Pharmaceutical Companies developing hESC Therapies

A. Geron
B. Novocell
C. Cell Cure Neurosciences Ltd
D. Cell Dynamics International
E. Advanced Cell Technology

IX. Featured Labs (Potential Customers)

A. Academic Labs
B. Private Labs
C. Government Labs
D. International Labs

X. Toxicology Testing Legislation

1. European Union to Ban Animal-Testing for Cosmetic Development in 2009

2. Responses to the European Ban on Animal Testing for Cosmetic Development

a. Overview
b. Skin Irritation
c. Eye Irritation
d. Skin Sensitisation
e. Mutagenicity/Genotoxicity
f. Reproductive Toxicity

3. EU Legislation Regarding Animal-Based Testing for Drug Discovery

XI. Product Development Suggestions

A. Product Categories

1. hESCs
2. hESC Derivative Cells
3. hESC Reporter Cells
4. hESC Antibodies
5. hESC Characterization & PCR Kits
6. hESC Qualified BME
7. hESC cDNA Libraries
8. hESC Growth Factors
9. hESC Media and Culture Reagents

B. Product Ideas & Suggestions

1. Areas of Underdeveloped Competition
2. Mouse ESC Products
3. iPS Cells Products
4. Non-animal-derived Culture Reagents for hESCs
5. Strategic Collaborations
6. Products for generating Pure ESC populations
7. hESC Toxicity Assay Kit

XII. Events of Interest

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Opportunities-in-Human-Embryonic-Stem-Cells-hESCs.html

According to “Ukraine Pharma - New Opportunities for Growth”, a new research report, Ukraine promises to be one of the most lucrative pharmaceutical markets in the world. In 2007, the Ukrainian pharmaceutical market grew by nearly 21% to register revenues in excess of US$ 2 Billion. The market is characterized by an increasing proportion of imported and high-priced drugs. In 2007, the average unit price of drugs sold in Ukraine increased by nearly 20%, strongly pushing the value of pharmaceutical sales, despite a relatively ordinary growth in sales volume.

The future outlook of the industry also seems very positive as the market is expected to be driven by a number of reforms recently proposed by the government. Factors such as increasing penetration of health insurance and increasing disposable incomes of consumers will also fuel growth. The lack of effective price controls and high margins are also expected to lure foreign players in this market. The country’s unstable political environment, however, will be the biggest hurdle for investments. But overall, the market is expected to grow strongly, exceeding US$ 4.5 Billion in revenues by 2012.

This report gives an extensive and objective analysis on the pharmaceutical market of Ukraine. It investigates both the past and present trends in the market, with its main focus on the future trends shaping the industry. The study discusses the performance of both the retail and hospital segments of the pharmaceutical market in detail and based on various present and future indicators, analyzes the future of these segments. This report gives valuable information to manufacturers/investors planning to enter the Ukrainian pharmaceutical market.

The Report Provides Forecasts on

*Macroeconomic Indicators
*Healthcare Indicators
*Population & Demographics
*Disease Profiles
*Total Pharmaceutical Market
*Retail Pharmaceutical Market
*Hospital Pharmaceutical Market

Key Player Profiling

Ukraine Pharma - New Opportunities for Growth” provides brief profiling on key players, both domestic and foreign, currently operating in the Ukraine pharmaceutical market. This section describes the revenues and growth of players in the total pharmaceutical market, retail market and hospital market. Performance of key drugs in various segments of the market has also been evaluated. Business profiles of top five players, Berlin Chemie, Sanofi Aventis, Novartis, Arterium and Darnitsa, have also been discussed in this report.

Table of Contents:

1. Analyst View
2. What Makes Ukraine so Lucrative
2.1 Robust Economic Growth
2.2 Improved Investment Climate
2.3 Growth of High-priced Drugs
2.4 Healthcare Infrastructure
3. Population & Demographics
4. The Pharmaceutical Market
4.1 Market Size
4.2 Imported & Domestically Manufactured Drugs
4.3 Leading Domestic & Foreign Manufacturers
4.4 Leading Pharmaceutical Distributors
5. The Retail Market
5.1 Market Size
5.2 Prescription & OTC Sales
5.3 Therapeutic Segmentation
5.4 Leading Domestic & Foreign Players
5.5 Leading Drugs
5.6 Price Characteristics of Drug Consumption
6. The Hospital Market
6.1 Market Size
6.2 Prescription & OTC Sales
6.3 Therapeutic Segmentation
6.4 Leading Domestic & Foreign Players
6.5 Leading Drugs
6.6 Price Characteristics of Drug Consumption
7. Opportunities
7.1 Clinical Trials Market
7.2 Contract Manufacturing
7.3 Medical Devices Market
8. Roadblocks
8.1 Unstable Political Environment
8.2 Declining Population
8.3 Lack of Effective Reimbursement System
8.4 Opaque Tax System
9. Forecasts
9.1 Critical Success & Risk Factors Shaping the Future
9.1.1 Critical Success Factors
9.1.2 Critical Risk Factors
9.2 Pharmaceutical Market
9.2.1 Retail Market
9.2.2 Hospital Market
10. Key Company Profiles
10.1 Berlin-Chemie
10.2 Sanofi-Aventis Group
10.3 Novartis
10.4 Arterium
10.5 Darnitsa Pharma

List of Figures:
Figure 2-1: Ukraine - Nominal GDP (in Billion US$), 2001-2007 & 2012F
Figure 2-2: Ukraine - Disposable Income per Head (in US$), 2001-2007E & 2012F
Figure 2-3: Ukraine - Healthcare Expenditure per Head (in US$), 2001-2007E & 2012F
Figure 2-4: Ukraine - Hospital Beds (per ‘000 Population), 2001-2007E & 2012F
Figure 2-5: Ukraine - Doctors (per ‘000 Population), 2002-2007E & 2012F
Figure 3-1: Ukraine - Population (in Million), 2001-2007E & 2012F
Figure 3-2: Ukraine - Population Breakup by Age Group (%), 2005-2007E & 2012F
Figure 3-3: Ukraine - Leading Causes of Death (%), 2005
Figure 3-4: Ukraine - Deaths due to Leading Causes (in Number), 2005
Figure 3-5: Ukraine - Forecast for Leading Causes of Death (%), 2030
Figure 3-6: US - Forecast for Deaths due to Leading Causes (in Number), 2030
Figure 4-1: Ukraine - Pharmaceutical Market (in Million US$), 2006 & 2007
Figure 4-2: Ukraine - Pharmaceutical Market (in Million Units), 2006 & 2007
Figure 4-3: Ukraine - Proportion of Generic & Branded Drugs (%)
Figure 4-4: Ukraine - Share of Retail & Hospital Segment in Pharmaceutical Market by Sales Value (%), 2006 & 2007
Figure 4-5: Ukraine - Share of Retail & Hospital Segment in Pharmaceutical Market by Sales Volume (%), 2006 & 2007
Figure 4-6: Ukarine - Pharmaceutical Imports (in Billion US$), 2005-2007E
Figure 4-7: Ukarine - Share of Imported & Domestically Manufactured Drugs in Pharmaceutical Market by Sales Value (%), 2006 & 2007E
Figure 4-8: Ukarine - Top 5 Pharmaceutical Importing Countries (in ‘000 Units) 2006 & 2007
Figure 5-1: Ukraine - Retail Pharmaceutical Market (in Million US$), 2006 & 2007
Figure 5-2: Ukraine - Retail Pharmaceutical Market (in Million Units), 2006 & 2007
Figure 5-3: Ukraine - Share of RX & OTC Drugs in Retail Pharmaceutical Market by Sales Value (%), 2006 & 2007
Figure 5-4: Ukraine - Share of RX & OTC Drugs in Retail Pharmaceutical Market by Sales Volume (%), 2006 & 2007
Figure 5-5: Ukraine - Retail Pharmaceutical Market by Therapeutic Area (%), 2007
Figure 6-1: Ukraine - Hospital Pharmaceutical Market (in Million US$), 2006 & 2007
Figure 6-2: Ukraine - Hospital Pharmaceutical Market (in Million Units), 2006 & 2007
Figure 6-3: Ukraine - Share of RX & OTC Drugs in Hospital Pharmaceutical Market by Sales Value (%), Q1-Q3 2007
Figure 6-4: Ukraine - Share of RX & OTC Drugs in Hospital Pharmaceutical Market by Sales Volume (%), Q1-Q3 2007
Figure 6-5: Ukraine - Hospital Pharmaceutical-Market by Therapeutic Area (%), Q1-Q3 2007
Figure 7-1: Ukraine - Medical Devices Market (in Million US$), 2007E & 2012F
Figure 9-1: Ukraine - Forecast for Pharmaceutical Market (in Million US$), 2008-2012
Figure 9-2: Ukraine - Forecast for Share of Retail & Hospital Segment in Pharmaceutical Market by Sales Value (%), 2008-2012
Figure 9-3: Ukraine - Forecast for Retail Pharmaceutical Market (in Million US$), 2008-2012
Figure 9-4: Ukraine - Forecast for Hospital Pharmaceutical Market (in Million US$), 2008-2012

List of Tables:
Table 2-1: Ukraine - Average Price per Trading Unit of Pharmaceuticals (in US$), 2006 & 2007
Table 2-2: Ukraine - Hospital Beds & Doctors w.r.t. Developed Countries (per ‘000 Population), 2007E
Table 4-1: Ukraine - Statistics of Top Players in Pharmaceutical Market (2007)
Table 4-2: Ukraine - Market Share of Top Pharmaceutical Distributors (%), 2006 & 2007
Table 5-1: Ukraine - Statistics of Top Players in Retail Pharmaceutical Market (2007)
Table 5-2: Ukraine - Statistics of Top 10 Drugs in Retail Pharmaceutical Market (2007)
Table 5-3: Ukraine - Price Characteristics of Drug Consumption in Retail Pharmaceutical Market
Table 6-1: Ukraine - Statistics of Top Players in Hospital Pharmaceutical Market (2007)
Table 6-2: Ukraine - Statistics of Top 20 Drugs in Hospital Pharmaceutical Market (Q1-Q3 2007)
Table 6-3: Ukraine - Average Retail Price per Drug in Hospital Pharmaceutical Market (in US$), Q1-Q3 2006 & Q1-Q3 2007
Table 9-1: Ukraine - Critical Sucess Factors for Pharmaceutical Market
Table 9-2: Ukraine - Critical Risk Factors for Pharmaceutical Market

For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Ukraine-Pharma-New-Opportunities-for-Growth.html

The Russian Clinical trials market has always enjoyed good returns since its inception, but its growth has been especially significant over the past few years, and is expected to post major growth in the future says our new report “Clinical Trials Market in Russia”.

The number of Clinical trials conducted in Russia increased to 615 in 2008, which is an increase of around 9% over 2007. The country has a highly centralized healthcare system. It implies that the country has highly specialized medical units that deliver healthcare services to all the patients with common symptoms under one roof. The patients normally follow the references for the tests and treatments given by the doctors. These references are to the highly specialized doctors in the big hospitals.

The Russian Clinical Trials have been enjoying significant foreign investments and accounts for more than two-third of the total clinical trials across the world. Russia sponsored 201 clinical trials in 2008, followed by American sponsors who conducted 145 clinical trials during the year. The clinical trials conducted by Russia include various therapy areas such as oncology, cardiology, pulmonology, etc. The country has large number of physicians who are willing to work as Clinical Research Investigators, to enhance their knowledge in their fields of specialization and earn a subsidiary income.

The government is also taking vital steps to bring healthcare reforms and to encourage the Russian drug makers having well-laid plans for the development of innovative drugs, especially vaccines to compete in the market at par with the foreign players. It has recently invested US$ 3.4 Billion to improve the utilization of resources in the Russian Clinical Trials Market.

Our report is the outcome of the extensive research and thorough analysis of the Russia Clinical Trials Market. It covers the various market dynamics that play upon the performance of the Russia Clinical Trials Market. The report will also help the client to assess the future outlook of the industry based on the government initiatives, regulatory framework and the growth pattern of the pharmaceutical industry.
Table of Contents:

1. Analyst View
2. Clinical Trials Market Overview
3. Russian Clinical Trials Market
3.1 Foreign Participation
3.2 Clinical Research Outsourcing
4. Market Performance and Forecast
4.1 Clinical Trials
4.2 Global Clinical Trial Study
4.3 Trials in Advanced Phases
4.4 Trials under Major Therapy Areas
4.5 Multi-national Sponsors
5. Patient Enrolment
5.1 Population
5.2 Disease Profile
5.3 Patient Recruitment
5.4 Patient Recruitment Rate
6. Regulatory Environment
7. Cost Analysis
7.1 Lab Fees
7.2 Hourly Rate of CRO
8. Clinical Trials and New Drugs Approval
8.1 FDA Inspections
8.2 FDA Approved Drugs
8.3 EMEA Approved Drugs
9. Key Market Trends
10. Industry Restraints
11. Key Players
11.1 Biocad
11.2 Novartis
11.3 Sanofi-Aventis
11.4 GlaxoSmithKline plc (GSK)
11.5 Pfizer

List of Tables

Table 2-1: Drug Discovery, Development and Approval Process
Table 4-1: Number of Clinical Trials by Top Five Sponsors (2008)
Table 4-2: Clinical Trials by Top Five International Study Sponsors (2008)
Table 4-3: Clinical Trials by Top Five Russian Study Sponsors (2008)
Table 5-1: Patient Recruitment Rates in Top Five Therapeutic Areas
Table 7-1: Lab Fees Comparison with UK and US (US$)
Table 7-2: Fees Charged by Local CROs in Comparison to International CROs (US$/Hour)
Table 8-1: New Drugs Approved by FDA in Q4 2008
Table 8-2: New Drugs approved by EMEA in Q4 2008
Table 9-1: Patient Investigator Fees in Comparison to India, US and Europe (US$)
Table 9-2: Population and City Distribution by Federal Region
Table 9-3: Top Ten Emerging Cities/Region by Number of New Sites (2008)

List of Charts

Figure 2-1: Share of Europe in Global Clinical Trials Market (2008)
Figure 2-2: European Clinical Trials Market by Player (%), 2008
Figure 2-3: European Clinical Research Outsourcing Market (Billion Euro) 2008 & 2012
Figure 2-4: Share of Eastern and Western Europe in Clinical Trials Market (2008 & 2012)
Figure 3-1: Share of Russian & International Sponsors in Clinical Trials (2007 & 2008)
Figure 3-2: Clinical Trials by Type of Operator (%)
Figure 4-1: Number of Clinical Trials (2005-2008)
Figure 4-2: Forecast for Number of Clinical Trials (2009-2012)
Figure 4-3: Share of Study Type in Clinical Trials (2004 to 2007)
Figure 4-4: Share of Study Type in Clinical Trials (2007 & 2008)
Figure 4-5: Number of Clinical Trials by Phase (2007 & 2008)
Figure 4-6: Clinical Trials by Therapy Area (%) 2007 & 2008
Figure 4-7: Phases of Clinical Trials by International Sponsors (Q3 2008)
Figure 5-1: Comparison of Population with Ukraine (Million) 2007 & 2008
Figure 5-2: Population Breakup by Age Group (%), 2008
Figure 5-3: Share of Population and Clinical Trials by Region
Figure 5-4: Leading Causes of Death (%) 2005 & 2030
Figure 5-5: Patient Recruitment by Phase of Study (%), 2008
Figure 8-1: Number of FDA Inspections since 1995 to 2008
Figure 8-2: FDA Inspection Results (%), 1995 to 2007
Figure 8-3: FDA Inspection Results (%), 2008
Figure 9-1: Qualified Specialists by Type (Thousand)
Figure 9-2: Urban & Rural Population Breakup (%) 2008
Figure 9-3: Pharmaceutical Market (Billion US$) 2007-2009
Figure 9-4: Forecast for Pharmaceutical Market (Billion US$), 2010-2012
For more information kindly visit
http://www.bharatbook.com/Market-Research-Reports/Clinical-Trials-Market-in-Russia.html

Choices in Cord Blood Banking Factors Influencing Parental Decision Making

Cord blood banking is increasingly being used to improve and save lives. Stem cells derived from umbilical blood have been used in more than 14,000 transplants worldwide to treat a wide range of blood diseases, genetic and metabolic disorders, immunodeficiencies and various forms of cancer. However, many expectant parents still do not fully understand the significance of cord blood storage. A study published in the Journal of Reproductive Medicine shows that a third of expectant parents are unaware of the option to preserve cord blood. Of the two-thirds who have some knowledge, 74% describe themselves as ¡§minimally informed.¨

Part 1 of this market report used proprietary data-derivation techniques to analyze conditions of the cord blood banking industry. Part 2 of this report used an end-user survey of expectant parents to identify and analyze the factors involved in the decision to privately store, publicly donate, or discard cord blood at birth. More than 1,200 expectation parents throughout the U.S., as well as Canada, Mexico, Europe, Asia, South/Central America, Australia and other regions answered the detailed survey between November 2008 and January 2009.

The report includes:

Sources through which expectant parents learn of cord blood banking
Rates of parental awareness of cord blood banking by gender, household income, geographic location, education, birth order, and other critical factors
Reasons parents cite as driving the decision to store cord blood
Factors influencing the decision for private vs. public storage of cord blood
Price sensitivity and quality expectations
Comparative analysis of quality variables among cord blood banks and parent perceptions of them
Parental responsiveness to health statistics
Differences in perspective based on global region, as well as differences due to location (city vs. suburban vs. rural)
Critical trends in cord blood banking and the factors influencing them
Competitive analysis of the Cord Blood Banking Industry, including:

U.S. Public Cord Blood Banks
U.S. Private Cord Blood Banks
International Public Cord Blood Banks
International Private Cord Blood Banks

Population Profiling: Characteristics of those highly/moderately/least likely to purchase cord blood banking services
Methods to effectively communicate with your target audience: Expectant Parents
And much more…

Table of Contents:

PART 1: CORD BLOOD BANKING, INDUSTRY OVERVIEW

I. Abstract

II. Cord Blood Stem Cells

A. Fetal Cord Blood Characteristics

B. Existing Treatments

C. Future Applications

III. Cord Blood Banking Industry
A. History
B. Private vs. Public Cord Blood Banks
1. U.S. Public Banks

a. Overview

b. Number of Public Banks

c. Geographic  Distribution

2. U.S. Private Banks
a. Overview

b. Number of U.S. Private Banks

c. Geographic  Distribution

3. Free Programs for U.S. Families with Medical Need

4. International Banks

a. Overview

b. Number Private Cord Blood Banks by International Region

IV. Market Characterization

A. List of U.S.  Private Cord Blood Banks

B. List of U.S. Public Cord Blood Banks

C. U.S. Mail-In Donation Cord Blood Banks

D. Breakdown of Canadian Cord Blood Banks – Public vs. Private / AABB Accredited vs. Non-Accredited

E. International Cord Blood Banks

1. Mexican Cord Blood Banks

a. Private Banks

b. Public Banking System

2. South/Central American Cord Blood Banks

a. Private Banks

b. Public Banking System

3. United Kingdom Cord Blood Banks

a. Private Banks

b. Public Banking System

4. European Cord Blood Banks

a. Private Banks

b. Public Banking System

5. Middle Eastern Cord Blood Banks

a. Private Banks

b. Public Banking System

6. Indian Cord Blood Banks

a. Private Banks

b. Public Banking System

7. Asian Cord Blood Banks

a. Private Banks

b. Public Banking System

8. Australian / New Zealand Cord Blood Banks

a. Private Australian and New Zealand Cord Blood Banks

b. Public Cord Blood Banks by Australian State

i. New South Wales

ii. Victoria

iii. Queensland

iv. Western Austalia, South Australia, & Tasmania

9. African Cord Blood Banks

a. Private Banks

b. Public Banking System

F. List of International Public Cord Blood Banks (Alphabetical by Country)

G. Worldwide List of AABB Accredited Cord Blood Facilities

V. United States Cord Blood Banking Legislation

A. U.S. State

B. U.S. Federal

1. Institute of Medicine Recommendations Study

a. Overview

b. Key Recommendations

c. IOM Study Shapes National Public Health Policy

2. Presidential Executive Order Expanding Approved Stem Cell Lines in Ethically Responsible Ways

a. Background

b. The Order

3. The Stem Cell Therapeutic and Research Act of 2005

a. Background

b. Current Status of the Act

VI. International Analysis – Trends, Policies and Industry Conditions (by Country)

A. NORTH & SOUTH  AMERICA

1. Canada

2. Mexico

3. United States

4. Brazil

5. Chile

6. Colombia

B. ASIA

1. China

2. Japan

3. Korea

4. Malaysia

5. Taiwan

6. Singapore

7. Thailand

C. INDIA

D. AUSTRALIA & NEW ZEALAND

E. EUROPE

1. European Union

a. Policy Overview

b. NETCORD Foundation
2. France

3. Germany & Austria

4. Italy

5. Netherlands

6. Spain

7. Poland

8. Russian Federation

9. United Kingdom

VII. Cost Analysis: Cord Blood Banking

A. Reasons for Variation in Cord Blood Pricing

1. Companies have Flexibility in the Pricing that they Set

2. Companies have Variables in the Services that they Offer

3. Variable Fee Breakdowns

B. Range of Pricing for U.S. Cord Blood Companies (1-100th percentiles)

1. U.S. Cord Blood Banking Price Range (1-100th%)

2. Lowest U.S. Pricing

3. Highest U.S. Pricing

4. Average U.S. Cord Blood Costs (25-75th percentiles)

5. Median Cost of U.S. Storage (50% percentile)

C. Range of Pricing for Canadian Cord Blood Companies (1-100th percentiles)

1. Canadian Cord Blood Banking Price Range (1-100th%)

2. Lowest Canadian Pricing

3. Highest Canadian. Pricing

4. Average Canadian. Cord Blood Costs (25-75th percentiles)

5. Median Cost of Canadian Storage (50% percentile)

VIII. Comparative Analysis of Quality Variables

A. Technical Variables

1. Vapor-Phase Storage vs. Liquid-Phase Storage

2. Cryo-bags vs. Cryo-vials

3. Pentastarch vs. Hetastarch

4. Computer Controlled vs. Manual Rate Freezing

5. Whole Sample vs. Volume Reduction

6. High-Control vs. Low-Control Aseptic Processing

B. Corporate Variables

1. Corporate Stability

2. Scientific Expertise

PART 2: EXPECTANT PARENTS, SURVEY RESULTS & FINDINGS

I. Survey Overview
A. Survey Population

B. Characterization of Market Survey Respondents

1. Geographic Distribution of Market Survey Respondents

2. Household Income Distribution of Survey Respondents

a. All Respondents

b. U.S. Respondents

3. Respondent Breakdown by Race

4. Respondent Breakdown by Gender

5. Respondent Breakdown by Level of Education

6. Respondent Breakdown by Location (City vs. Suburban vs. Rural)

7. Regional Breakdown of U.S. Respondents

8. Demographic Conclusions

II. Rates of Awareness: Unaware / Minimally Informed / Moderately Informed / Knowledgeable

A. Overall

B. By Gender

C. By Household Income

1. All Respondents

2. U.S. Respondents

D. By Education

E. By Race

F. By Geographic Location

1. Region within U.S.

2. Location (City vs. Suburban vs. Rural)

G. By Number of Existing Children within Family (e.g. Birth Order)

III. Factors Influencing Awareness

A. Personal Exposure: Relative Impact of Family, Co-Workers, Peers

B. Informational Sources: Information Sites, Books Medical Pamphlets, Government Sources

C. Medical Exposure: General Doctors, Ob / Gyn, Midwifes, Nurse, Other
D. Promotional Sources:  Internet Advertisements, Print Advertisements, Radio, TV, Other

IV. Factors Influencing Parental Decision-Making

A. Factors Influencing the Decision Not to Store Cord Blood

1.  Knowledge Level

2.  Price Sensitivity

3.  Safety Concerns

4.  Lack of Access

5.  Misconceptions

B. Factors Influencing the Decision for Private vs. Public Storage of Cord Blood

1. Ethical Beliefs

2. Gender

3. Total Household Income

4. Level of Education (Highest Level Achieved by at Least One Parent)

5. Race

6. Geographic Location

a. Region within U.S.

b. City vs. Suburban vs. Rural

7.  Access to Reliable Healthcare

8.  Number of Existing Children within Family (Birth Order)

9.  Source of Knowledge

10. Perceived Support of Medical Staff

11. Family Medical History

C. International Analysis of Cord Blood Banking Perceptions (Region-by-Region)

V. Parental Responsiveness to Health Statistics

A.  Overview

B.  Health Statistics

C.  Health Statistic Conclusions

VI. Parental Expectations

A. Quality of Services

B. Willingness to Educate/Inform

C. Reputability of Organization

VII. Trends

A. Rates of Cord Blood Storage (units per year)

B. Rates of Parental Awareness

C. Cord Blood Research Publication Rates

D. Cord Blood Research Funding Levels

E. Cord Blood Patent Breakdown

F.  Rates of Cord Blood Research Product Development

VIII. Informative Websites: Online Sources Utilized by Expectant Parents

A. Overview of Websites

1. Information Only

2. Commercial Affiliation

B. Dominant Regional Websites (International Analysis)

C. Most Important Criteria Used to Identify Sites to Inform Decision-Making

D. Underlying Reasons for Visiting Online Resources

IX. Conclusions

A. Traits of a “Model Customer”

1. “Model Customer” for a Private Cord Blood Bank

2. “Model Customer” for a Public Cord Blood Bank

B. Ideal Price Range

C. Approaches for Communicating with Expectant Parents

For more please visit
http://www.bharatbook.com/Market-Research-Reports/Choices-in-Cord-Blood-Banking-Factors-Influencing-Parental-Decision-Making.html